Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Susan R Rheingold, Lingyun Ji, Lia Gore, Xinxin Xu, Deepa Bhojwani, Nirali N. Shah, Elizabeth A. Raetz, Mignon L. Loh, Maureen M. O'Brien

Blood (2023) 142 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2023-183103

Published: 2023

Journal Articles

Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children's Oncology Group Study

Xiaotu Ma, Lingyun Ji, Yanling Liu, Ying Shao, Heather Mulder, Pandurang Kolekar, Quang Tran, Jinghui Zhang, John Easton, William L. Carroll, Patrick A. Brown, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 1048–1049.

https://doi.org/10.1182/blood-2022-166489

Published: 2022

Journal Articles

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Teena Bhatla, Laura Hogan, Xinxin Xu, Lingyun Ji, Andrew J. Carroll, Nyla A. Heerema, Mary Shago, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3476–3477.

https://doi.org/10.1182/blood-2022-166523

Published: 2022

Journal Articles

CD22 low /Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

Ernesto Diaz-Flores, Astrid Wintering, Kenichi Ishiyama, Stanley Tamaki, Courtney Tamaki, Josh Fandel, Lingyun Ji, Brent Wood, Constance M. Yuan, Nirali N. Shah, Maureen M. O'Brien, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 614.

https://doi.org/10.1182/blood-2021-149037

Published: 2021

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Teena Bhatla, Michael Borowitz, Elizabeth A. Raetz, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 363.

https://doi.org/10.1182/blood-2021-147946

Published: 2021

Journal Articles

Preexisting or therapy-induced mutations in relapsed acute lymphoblastic leukemia?

Paul S. Gaynon, Etan Orgel, Lingyun Ji

Blood (2020) 136 (19): 2233–2235.

https://doi.org/10.1182/blood.2020005258

Published: 2020

Journal Articles

Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study

Teena Bhatla, MD, Laura Hogan, MD, Xinxin Xu, MS, Lingyun Ji, Andrew J Carroll, PhD, Nyla A Heerema, PhD, Mary Shago, PhD, Lia Gore, MD, James A. Whitlock, MD, Stephen P Hunger, MD, Mignon L. Loh, MD, Patrick A. Brown, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-136364

Published: 2020

Journal Articles

Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children

Julie Jaffray, Char Witmer, Sarah H. O’Brien, Rosa Diaz, Lingyun Ji, Emily Krava, Guy Young

Blood (2020) 135 (3): 220–226.

https://doi.org/10.1182/blood.2019002260

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning

Blood (2019) 134 (Supplement_1): 635.

https://doi.org/10.1182/blood-2019-126128

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Risk Factors for Hospital-Acquired Venous Thromboembolism in Children: Findings from the Children's Hospital-Acquired Thrombosis (CHAT) Registry

Brian R. Branchford, MD, Julie Jaffray, MD, Stacy E. Croteau, MD, Michael Silvey, DO, Nihal Bakeer, MBBS, James D. Cooper, MD, John H. Fargo, DO, Lingyun Ji, PhD, Richard Sposto, PhD, Jemily Malvar, Emily Krava, Amy Stillings, Neil A Goldenberg, MD PhD, Guy Young, Arash Mahajerin, MD MS

Blood (2018) 132 (Supplement 1): 142.

https://doi.org/10.1182/blood-2018-99-119968

Published: 2018

Journal Articles

Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331

Laura Brook Hogan, MD, Teena Bhatla, MD, Sue Rheingold, MD, Lingyun Ji, PhD, Xinxin Xu, Elizabeth A. Raetz, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Patrick Brown, MD

Blood (2018) 132 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2018-99-112269

Published: 2018

Journal Articles

Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children

Julie Jaffray, MD, Sarah H. O'Brien, MD MSc, Char M Witmer, MDMSCE, Rosa Diaz, MD, Lingyun Ji, PhD, Richard Sposto, PhD, Emily Krava, Guy Young

Blood (2018) 132 (Supplement 1): 139.

https://doi.org/10.1182/blood-2018-99-115615

Published: 2018

Journal Articles

The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen

Ibrahim Aldoss, MD, Vinod Pullarkat, MD, Daniel Martinez, MD, Lingyun Ji, Dan Douer, MD

Blood (2013) 122 (21): 3915.

https://doi.org/10.1182/blood.V122.21.3915.3915

Published: 2013

Journal Articles

Kaolin-Activated Thromboelastography in Hemophilia Patients Discriminates Responses to rFVIIa Better Than Tissue Factor.

Ru Zhang, MD, Dena Yassin, Lingyun Ji, Robert Miller, Diane J. Nugent, MD, Guy Young, MD

Blood (2008) 112 (11): 2277.

https://doi.org/10.1182/blood.V112.11.2277.2277

Published: 2008

Journal Articles

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Richard H. Ko, MD, Lingyun Ji, MS, Richard Sposto, PhD, Phillip Barnette, MD, Bruce Bostrom, MD, Raymond Hutchinson, MD, Elizabeth Raetz, MD, Nita Seibel, MD, Clare Twist, MD, Elena Eckroth, BA, Paul Gaynon, MD, Mignon Loh, MD

Blood (2007) 110 (11): 854.

https://doi.org/10.1182/blood.V110.11.854.854

Published: 2007

NARROW

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children's Oncology Group Study

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

CD22 low /Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

Preexisting or therapy-induced mutations in relapsed acute lymphoblastic leukemia?

Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study

Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children

The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Risk Factors for Hospital-Acquired Venous Thromboembolism in Children: Findings from the Children's Hospital-Acquired Thrombosis (CHAT) Registry

Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331

Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children

The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen

Kaolin-Activated Thromboelastography in Hemophilia Patients Discriminates Responses to rFVIIa Better Than Tissue Factor.

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only